{"analyses":[{"ciLowerLimit":"-11.7","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.3","groupDescription":"6 Month Analysis","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of the QD schedule relative to the BID schedule was deduced if the lower bound of the 95% CI for the MCyRRQD minus MCyRRBID difference was greater than or equal to -15%.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Risk Difference (RD)","paramValue":"1.8","testedNonInferiority":true},{"ciLowerLimit":"-9.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.6","groupDescription":"6 Month Analysis","groupIds":["OG002","OG003"],"nonInferiorityComment":"Non-inferiority of 100 mg QD Total Daily Dose relative to 140 mg QD Total Daily Dose was deduced if the lower bound of the 95% CI difference was greater than or equal to -15%.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Risk Difference (RD)","paramValue":"4.2","testedNonInferiority":true},{"ciLowerLimit":"-11.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"14.1","groupDescription":"24 Month Analysis","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of the QD schedule relative to the BID schedule was deduced if the lower bound of the 95% CI for the MCyRRQD minus MCyRRBID difference was greater than or equal to -15%.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Risk Difference (RD)","paramValue":"1.4","testedNonInferiority":true},{"ciLowerLimit":"-11.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"14.1","groupDescription":"24 Month Analysis","groupIds":["OG002","OG003"],"nonInferiorityComment":"Non-inferiority of 100 mg QD Total Daily Dose relative to 140 mg QD Total Daily Dose was deduced if the lower bound of the 95% CI difference was greater than or equal to -15%.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Risk Difference (RD)","paramValue":"1.4","testedNonInferiority":true}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.8","upperLimit":"81.5","value":"72.4"},{"groupId":"OG001","lowerLimit":"59.7","upperLimit":"80.0","value":"70.6"},{"groupId":"OG002","lowerLimit":"63.0","upperLimit":"82.4","value":"73.6"},{"groupId":"OG003","lowerLimit":"58.5","upperLimit":"79.0","value":"69.4"}]}],"title":"6 Month"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.8","upperLimit":"85.4","value":"77.0"},{"groupId":"OG001","lowerLimit":"65.1","upperLimit":"84.2","value":"75.6"},{"groupId":"OG002","lowerLimit":"66.8","upperLimit":"85.4","value":"77.0"},{"groupId":"OG003","lowerLimit":"65.1","upperLimit":"84.2","value":"75.6"}]}],"title":"24 Month"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"87"},{"groupId":"OG003","value":"86"}],"units":"Participants"}],"description":"CyR was based on the number of Ph+ metaphases among cells in metaphase on a BM sample. The criteria for CyR were as follows: complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; PCyR: \\>0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: \\>35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: \\>65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: \\>95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of CCyR or PCyR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received either 100 mg or 140 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG000","title":"QD Dasatinib"},{"description":"Participants received either 50 mg or 70 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG001","title":"BID Dasatinib"},{"description":"Participants received either 100 mg QD or 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG002","title":"Total Daily Dose 100 mg"},{"description":"Participants received either 140 mg QD or 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG003","title":"Total Daily Dose 140 mg"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-intolerant participants with available data were summarized.","reportingStatus":"POSTED","timeFrame":"6 months, 24 months","title":"Percent of Participants Intolerant to Imatinib With MCyR at 6 Months and at 24 Months Follow-Up, by QD and BID Schedules and by Total Daily Dose","type":"SECONDARY","unitOfMeasure":"percentage of participants"}